Extracellular matrix rigidity modulates neuroblastoma cell differentiation and N-myc expression

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Lam, Wilbur A ^a,b   Cao, Lizhi ^a   Umesh, Vaibhavi ^a   Keung, Albert J ^c   Sen, Shamik ^a   Kumar, Sanjay ^a  

^a University of California at Berkeley   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR N MYC; TUMOR MARKER; UNCLASSIFIED DRUG; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RETINOIC ACID;

ARTICLE; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MECHANOTRANSDUCTION; NERVE GROWTH; NEUROBLASTOMA CELL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL SHAPE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROBLASTOMA; PATHOLOGY; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; TRETINOIN;

EID: 77949567242     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-35     Document Type: Article

References (48)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007, 369:2106-2120. 10.1016/S0140-6736(07)60983-0, 17586306.
2. Yoon KJ, Danks MK. Cell adhesion molecules as targets for therapy of neuroblastoma. Cancer Biol Ther 2009, 8:306-311. 10.1158/1535-7163.MCT-09-0300, 19197150.
3. Poomthavorn P, Wong SH, Higgins S, Werther GA, Russo VC. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer 2009, 16:991-1004. 10.1677/ERC-08-0340, 19423615.
4. Higgins S, Wong SH, Richner M, Rowe CL, Newgreen DF, Werther GA, Russo VC. Fibroblast growth factor 2 reactivates G1 checkpoint in SK-N-MC cells via regulation of p21, inhibitor of differentiation genes (Id1-3), and epithelium-mesenchyme transition-like events. Endocrinology 2009, 150:4044-4055. 10.1210/en.2008-1797, 19477940.
5. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003, 197:185-192. 10.1016/S0304-3835(03)00108-3, 12880980.
6. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173. 10.1056/NEJM199910143411601, 10519894.
7. Adamson PC, Matthay KK, O'Brien M, Reaman GH, Sato JK, Balis FM. A phase 2 trial of all-trans-retinoic acid in combination with interferon-alpha2a in children with recurrent neuroblastoma or Wilms tumor: A Pediatric Oncology Branch, NCI and Children's Oncology Group Study. Pediatr Blood Cancer 2007, 49:661-665. 10.1002/pbc.21011, 16900483.
8. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009, 27:1007-1013. 10.1200/JCO.2007.13.8925, 19171716.
9. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 1985, 313:404-406. 10.1038/313404a0, 3855502.
10. Pan J, Kao YL, Joshi S, Jeetendran S, Dipette D, Singh US. Activation of Rac1 by phosphatidylinositol 3-kinase in vivo: role in activation of mitogen-activated protein kinase (MAPK) pathways and retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J Neurochem 2005, 93:571-583. 10.1111/j.1471-4159.2005.03106.x, 15836616.
11. Clagett-Dame M, McNeill EM, Muley PD. Role of all-trans retinoic acid in neurite outgrowth and axonal elongation. J Neurobiol 2006, 66:739-756. 10.1002/neu.20241, 16688769.
12. Rozzo C, Chiesa V, Ponzoni M. Integrin up-regulation as marker of neuroblastoma cell differentiation: correlation with neurite extension. Cell Death Differ 1997, 4:713-724. 10.1038/sj.cdd.4400304, 16465284.
13. Hahn M, Glass T, Koke J. Extracellular matrix effects on a neuroblastoma cell line. Cytobios 2000, 102:7-19.
14. Matsushima H, Bogenmann E. Modulation of neuroblastoma cell differentiation by the extracellular matrix. Int J Cancer 1992, 51:727-732. 10.1002/ijc.2910510511, 1612781.
15. Kidowaki T, Thiele CJ, Kleinman HK, Israel MA. Matrix proteins induce neuroblastoma cell differentiation without altering cell growth. Pathobiology 1991, 59:316-323. 10.1159/000163670, 1910526.
16. Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. Science 2005, 310:1139-1143. 10.1126/science.1116995, 16293750.
17. Janmey PA, Winer JP, Murray ME, Wen Q. The hard life of soft cells. Cell Motil Cytoskeleton 2009, 66:597-605. 10.1002/cm.20382, 19479819.
18. Yeung T, Georges PC, Flanagan LA, Marg B, Ortiz M, Funaki M, Zahir N, Ming W, Weaver V, Janmey PA. Effects of substrate stiffness on cell morphology, cytoskeletal structure, and adhesion. Cell Motil Cytoskeleton 2005, 60:24-34. 10.1002/cm.20041, 15573414.
19. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 2009, 28:113-127. 10.1007/s10555-008-9173-4, 2658728, 19153673.
20. Sen S, Dong M, Kumar S. Isoform-specific contributions of alpha-actinin to glioma cell mechanobiology. PLoS One 2009, 4:e8427. 10.1371/journal.pone.0008427, 2793025, 20037648.
21. Zhang X, Jiang G, Cai Y, Monkley SJ, Critchley DR, Sheetz MP. Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol 2008, 10:1062-1068. 10.1038/ncb1765, 2746969, 19160486.
22. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126:677-689. 10.1016/j.cell.2006.06.044, 16923388.
23. Flanagan LA, Ju YE, Marg B, Osterfield M, Janmey PA. Neurite branching on deformable substrates. Neuroreport 2002, 13:2411-2415. 10.1097/00001756-200212200-00007, 2408859, 12499839.
24. Georges PC, Miller WJ, Meaney DF, Sawyer ES, Janmey PA. Matrices with compliance comparable to that of brain tissue select neuronal over glial growth in mixed cortical cultures. Biophys J 2006, 90:3012-3018. 10.1529/biophysj.105.073114, 1414567, 16461391.
25. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, Hammer DA, Weaver VM. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254. 10.1016/j.ccr.2005.08.010, 16169468.
26. Alexander NR, Branch KM, Parekh A, Clark ES, Iwueke IC, Guelcher SA, Weaver AM. Extracellular matrix rigidity promotes invadopodia activity. Curr Biol 2008, 18:1295-1299. 10.1016/j.cub.2008.07.090, 2555969, 18718759.
27. Parekh A, Weaver AM. Regulation of cancer invasiveness by the physical extracellular matrix environment. Cell Adh Migr 2009, 3:288-292.
28. Munevar S, Wang Y, Dembo M. Traction force microscopy of migrating normal and H-ras transformed 3T3 fibroblasts. Biophys J 2001, 80:1744-1757. 10.1016/S0006-3495(01)76145-0, 1301364, 11259288.
29. Ulrich TA, de Juan Pardo EM, Kumar S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 2009, 69:4167-4174. 10.1158/0008-5472.CAN-08-4859, 19435897.
30. Kostic A, Lynch CD, Sheetz MP. Differential matrix rigidity response in breast cancer cell lines correlates with the tissue tropism. PLoS One 2009, 4:e6361. 10.1371/journal.pone.0006361, 2709918, 19626122.
31. Guo WH, Wang YL. Retrograde fluxes of focal adhesion proteins in response to cell migration and mechanical signals. Mol Biol Cell 2007, 18:4519-4527. 10.1091/mbc.E07-06-0582, 2043553, 17804814.
32. Huveneers S, Danen EH. Adhesion signaling - crosstalk between integrins, Src and Rho. J Cell Sci 2009, 122:1059-1069. 10.1242/jcs.039446, 19339545.
33. Matthews BD, Overby DR, Mannix R, Ingber DE. Cellular adaptation to mechanical stress: role of integrins, Rho, cytoskeletal tension and mechanosensitive ion channels. J Cell Sci 2006, 119:508-518. 10.1242/jcs.02760, 16443749.
34. Puklin-Faucher E, Sheetz MP. The mechanical integrin cycle. J Cell Sci 2009, 122:179-186. 10.1242/jcs.042127, 19118210.
35. Solon J, Levental I, Sengupta K, Georges PC, Janmey PA. Fibroblast adaptation and stiffness matching to soft elastic substrates. Biophys J 2007, 93:4453-4461. 10.1529/biophysj.106.101386, 2098710, 18045965.
36. Pelham RJ, Wang Y. Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc Natl Acad Sci USA 1997, 94:13661-13665. 10.1073/pnas.94.25.13661, 28362, 9391082.
37. Peyton SR, Putnam AJ. Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. J Cell Physiol 2005, 204:198-209. 10.1002/jcp.20274, 15669099.
38. Winer JP, Janmey PA, McCormick ME, Funaki M. Bone marrow-derived human mesenchymal stem cells become quiescent on soft substrates but remain responsive to chemical or mechanical stimuli. Tissue Eng Part A 2009, 15:147-154. 10.1089/ten.tea.2007.0388, 18673086.
39. Bao G, Suresh S. Cell and molecular mechanics of biological materials. Nat Mater 2003, 2:715-725. 10.1038/nmat1001, 14593396.
40. Sugimoto T, Sawada T, Matsumura T, Horii Y, Kemshead JT, Suzuki Y, Okada M, Tagaya O, Hino T. Morphological differentiation of human neuroblastoma cell lines by a new synthetic polyprenoic acid (E5166). Cancer Res 1987, 47:5433-5438.
41. Miloso M, Villa D, Crimi M, Galbiati S, Donzelli E, Nicolini G, Tredici G. Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent. J Neurosci Res 2004, 75:241-252. 10.1002/jnr.10848, 14705145.
42. Woo CW, Lucarelli E, Thiele CJ. NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number. Oncogene 2004, 23:1522-1530. 10.1038/sj.onc.1207267, 14691455.
43. Fan L, Iyer J, Zhu S, Frick KK, Wada RK, Eskenazi AE, Berg PE, Ikegaki N, Kennett RH, Frantz CN. Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res 2001, 61:1073-1079.
44. Norris MD, Burkhart CA, Marshall GM, Weiss WA, Haber M. Expression of N-myc and MRP genes and their relationship to N-myc gene dosage and tumor formation in a murine neuroblastoma model. Med Pediatr Oncol 2000, 35:585-589. 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.0.CO;2-P, 11107123.
45. Hashimoto H, Daimaru Y, Enjoji M, Nakagawara A. N-myc gene product expression in neuroblastoma. J Clin Pathol 1989, 42:52-55. 10.1136/jcp.42.1.52, 1141790, 2921345.
46. van Golen CM, Soules ME, Grauman AR, Feldman EL. N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 2003, 22:2664-2673. 10.1038/sj.onc.1206362, 12730680.
47. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006, 66:2826-2833. 10.1158/0008-5472.CAN-05-0854, 16510605.
48. Pession A, Tonelli R. The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr Cancer Drug Targets 2005, 5:273-283. 10.2174/1568009054064606, 15975048.